BioMarin Misses Q1, Raises Revenue Guidance

BioMarin Pharmaceuticals Q1 2026 earnings missed Wall Streets revenue expectations, with sales up 2.8% to $766.2M and adjusted EPS at $0.76, below the forecast $0.91. However, they beat on adjusted EBITDA and raised full-year revenue guidance by 14.8% to $3.88B. The company credits the acquisition of Amicus Therapeutics for this growth. Operating margins slipped, but free cash flow margin improved. Despite a flat stock price, analysts predict 19.5% revenue growth over the next year, keeping the growth story alive for BioMarin. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c3c57176308f97b0